Trial · NCT00599326
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
NCT00599326, Phase 3, Completed, University of Texas Southwestern Medical Center; results first posted 2014-02-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda. Trials, record NCT00599326. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00599326
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
- NCT number
- NCT00599326
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 10 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Porphyria Cutanea Tarda
- Interventions
- Deferasirox
- First posted
- 2008-01-23
- Last updated
- 2014-02-10
- Results first posted
- 2014-02-10
- Limitations and caveats
10 patients were enrolled, of which 8 were compliant with therapy and had evaluable data. Of the 2 patients dropped from the study, one patient was lost to follow-up after 2 months and another was noncompliant with medication dosing.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Showing Reduction or Elimination of Skin Blistering | Within 6 months of treatment. | The present trial was undertaken to determine if oral deferasirox could be useful in the treatment of PCT. Monthly clinic visits with a physical examination was conducted to assess the skin for blisters. |
| Secondary | Number of Participants Showing Decrease in Ferritin and Urinary Porphyrin Level | 6 months | Patients with PCT usually have normal or elevated serum iron and ferritin levels as well as increased iron absorption. Phlebotomy is conducted to analyzes the ferritin levels. Urine collection is performed and samples of the urine are analyzed for porphyrin levels. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Showing Reduction or Elimination of Skin Blistering | Within 6 months of treatment. | participants | NUMBER | |
| SECONDARY | Number of Participants Showing Decrease in Ferritin and Urinary Porphyrin Level | 6 months | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Showing Reduction or Elimination of Skin Blistering | Deferasirox | Elimination | 0 | participants | |
| Number of Participants Showing Reduction or Elimination of Skin Blistering | Deferasirox | Reduction | 8 | participants | |
| Number of Participants Showing Decrease in Ferritin and Urinary Porphyrin Level | Deferasirox | Decrease in ferritin level | 8 | participants | |
| Number of Participants Showing Decrease in Ferritin and Urinary Porphyrin Level | Deferasirox | Decrease in urinary porphyrin level | 6 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Deferasirox | 10 | |
| Overall Study | COMPLETED | Deferasirox | 8 | |
| Overall Study | NOT COMPLETED | Deferasirox | 2 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain (Mild) | Gastrointestinal disorders | Deferasirox | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Deferasirox | ||
| Total, other adverse events | Deferasirox | 1 | 10 |
| Total, serious adverse events | Deferasirox | 0 | 10 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22911183 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00599326
GET https://conductscience.org/api/trials/v1/NCT00599326/registered